Real-world results are out for cystic fibrosis combo
Many more patients discontinued lumacaftor-ivacaftor than in pivotal clinical trials: researchers
Lumacaftor-ivacaftor treatment is associated with improved outcomes among adolescents and adults with cystic fibrosis who tolerate the therapy, a real-world study shows.
French researchers examined outcomes after the combination’s release in France in December 2015.
